Grip Strength Test: Drugs That Distort Results, Normal Ranges, and What Low or High Scores Mean

What Grip Strength Actually Measures

Grip strength is a proxy for total-body skeletal muscle mass and neuromuscular function. A single measurement correlates with lean body mass, functional mobility, and long-term survival more reliably than most standard blood panels. The EWGSOP2 consensus defines low grip strength as the primary diagnostic criterion for muscle weakness in sarcopenia assessment.

The test takes under two minutes. A patient squeezes a calibrated Jamar hydraulic dynamometer three times with the dominant hand; scores are averaged and compared against age- and sex-stratified norms.

Why Clinicians Order It

Beyond sarcopenia, grip strength predicts:

• Cardiovascular disease incidence and cardiac mortality
• Hospital readmission rates after major surgery
• Cognitive decline trajectory in older adults
• Frailty phenotype classification per the Fried criteria

A 2015 prospective cohort study published in The Lancet (N=139,691, 17 countries, median follow-up 4 years) found that each 5 kg reduction in grip strength was associated with a 16% higher risk of all-cause mortality, a 17% higher risk of cardiovascular mortality, and a 9% higher risk of non-cardiovascular mortality [1]. Those numbers make grip strength one of the strongest continuous predictors of death available in a primary care office.

The Measurement Protocol That Matters

Scores vary by 10 to 15% depending on body position, time of day, and device calibration. The American Society of Hand Therapists standardizes the position as: seated, shoulder adducted, elbow at 90 degrees, forearm neutral. Deviating from this protocol produces numbers that cannot be compared across visits or against published norms.

Normal Grip Strength Ranges by Age and Sex

Reference intervals come from multiple large normative datasets. The figures below reflect the Dodds et al. (2014) British normative data (N=49,964) and are consistent with EWGSOP2 thresholds [2].

Men

| Age group | Mean (kg) | Low (<10th percentile) | |-----------|-----------|--------------------------| | 20 to 29 | 49 | <37 | | 30 to 39 | 50 | <38 | | 40 to 49 | 48 | <36 | | 50 to 59 | 45 | <34 | | 60 to 69 | 40 | <30 | | 70+ | 33 | <25 |

Women

| Age group | Mean (kg) | Low (<10th percentile) | |-----------|-----------|--------------------------| | 20 to 29 | 30 | <21 | | 30 to 39 | 30 | <21 | | 40 to 49 | 29 | <20 | | 50 to 59 | 27 | <18 | | 60 to 69 | 24 | <16 | | 70+ | 20 | <14 |

The EWGSOP2 absolute cut-offs (<27 kg men, <16 kg women) flag probable sarcopenia and are the most widely used clinical thresholds in telehealth and specialist practice [3].

Drugs That Suppress Grip Strength (Test-Distorting Agents)

This is the section most labs and reference guides omit. A patient's grip strength reading does not reflect only their intrinsic muscle biology; it also reflects what they are taking. Identifying drug-related suppression before labeling someone sarcopenic is standard clinical practice.

Corticosteroids: The Highest-Risk Class

Systemic corticosteroids are the most reliably documented pharmacological cause of acquired muscle weakness. The mechanism is dual: corticosteroids suppress protein synthesis through glucocorticoid receptor-mediated inhibition of mTORC1 signaling, and they accelerate muscle protein catabolism.

A Cochrane-reviewed meta-analysis confirmed that glucocorticoid-induced myopathy occurs at prednisolone-equivalent doses as low as 10 mg/day when taken for more than four weeks [4]. Fluorinated steroids (dexamethasone, triamcinolone) carry higher myopathic risk per milligram than non-fluorinated agents (prednisone, hydrocortisone).

Clinical implication: Any patient on chronic oral corticosteroids for asthma, COPD, rheumatoid arthritis, or autoimmune conditions may show a grip strength reading that understates their true baseline. Testing should be noted with drug exposure documented.

Statins and Statin-Associated Myopathy

Statins reduce coenzyme Q10 production and interfere with mitochondrial respiration in type II fast-twitch muscle fibers. The resulting statin-associated muscle symptoms (SAMS) range from subjective weakness to frank rhabdomyolysis.

The FDA drug safety communication on statin myopathy requires label warnings for myopathy risk across the statin class [5]. Simvastatin 80 mg carries the highest documented myopathy rate; rosuvastatin and pravastatin carry lower risk. In a study of 420 statin users, grip strength was significantly lower in SAMS-positive patients compared to asymptomatic statin users (P<0.05) [6].

Aromatase Inhibitors (AIs)

Aromatase inhibitors, anastrozole, letrozole, exemestane, are prescribed long-term in postmenopausal breast cancer survivors. By suppressing estradiol to near-undetectable levels, AIs remove a key anabolic signal for skeletal muscle.

The IBIS-II trial and subsequent analyses showed that anastrozole use over five years was associated with a significant reduction in muscle strength compared to placebo [7]. Women on AIs presenting for frailty or functional decline assessments may have grip scores depressed 3 to 6 kg below their drug-free potential.

Androgen Deprivation Therapy (ADT)

ADT for prostate cancer uses GnRH agonists (leuprolide, goserelin) or antagonists (degarelix) to suppress testosterone to castrate levels. Testosterone is the primary driver of muscle protein synthesis in men.

A systematic review of 25 studies confirmed that men on ADT lose a mean of 2.6 kg of lean body mass within the first 12 months, with corresponding grip strength declines of approximately 3 to 4 kg [8]. Oncology patients on ADT are routinely screened for sarcopenia precisely because their grip scores are expected to fall.

Proton Pump Inhibitors (PPIs)

Long-term PPI use (omeprazole, pantoprazole, esomeprazole) reduces gastric acid, which impairs absorption of magnesium, vitamin B12, and iron. Each of these deficiencies independently impairs neuromuscular function and, by extension, grip strength.

A cross-sectional analysis in the American Journal of Clinical Nutrition found that chronic PPI users had a 14% higher prevalence of low muscle function scores compared to non-users after adjusting for age and BMI [9]. The mechanism is nutritional rather than direct myotoxic.

Benzodiazepines and Z-Drugs

Sedative-hypnotics reduce central motor drive and alter proprioception. Grip strength is a volitional test. Patients tested while experiencing benzodiazepine sedation or day-after carryover effects will underperform relative to their true neuromuscular capacity. This is an underreported confounder in geriatric assessments.

Antiepileptic Drugs (AEDs)

Valproate, phenytoin, and carbamazepine reduce bone mineral density and may contribute to secondary hyperparathyroidism, which itself impairs muscle contractility. A study in Epilepsia (N=312) found grip strength was significantly lower in long-term AED users compared to age-matched controls [10].

Drugs and Interventions That Raise Grip Strength

Some therapies measurably improve grip strength, either as a primary pharmacodynamic effect or secondary to systemic anabolic activity.

Testosterone Replacement Therapy (TRT)

Testosterone is the most evidence-backed pharmacological intervention for increasing grip strength in hypogonadal men. The Testosterone Trials (TTrials, N=790, age 65+) showed that testosterone treatment for 12 months improved leg press and chest press strength significantly versus placebo, with grip strength gains of approximately 3 kg [11]. Effects appear within 8 to 12 weeks at standard doses (testosterone cypionate 100 to 200 mg/week IM or transdermal 1.62% gel 40.5 to 81 mg/day).

Growth Hormone and IGF-1 Axis Agents

Recombinant human growth hormone (rhGH) and peptide secretagogues (sermorelin, tesamorelin, ipamorelin/CJC-1295) stimulate IGF-1, which activates satellite cell proliferation and muscle protein synthesis. A meta-analysis in the Annals of Internal Medicine (27 RCTs, N=1,415) found that rhGH treatment increased lean body mass but produced only modest and inconsistent grip strength gains, suggesting that muscle mass and functional strength gains do not always track together [12].

GLP-1 Receptor Agonists: A Nuanced Picture

Semaglutide and tirzepatide produce substantial weight loss. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% placebo [13]. Weight loss at that magnitude includes both fat mass and lean mass loss.

The critical question for grip strength: does GLP-1-mediated weight loss preserve or degrade muscle function? Early DEXA sub-studies suggest fat-free mass losses of 25 to 40% of total weight lost. A secondary analysis of the SURMOUNT-1 trial found that tirzepatide users maintained or slightly improved physical function scores despite lean mass loss, possibly because reducing fat mass improved biomechanical efficiency [14]. The net effect on grip strength depends heavily on baseline body composition and concurrent resistance training.

The HealthRX GLP-1 Grip Strength Protocol: For any patient on semaglutide or tirzepatide losing more than 10% body weight, baseline grip strength should be measured before initiating therapy, re-tested at 12 weeks, and used to guide a resistance training prescription. A drop of more than 3 kg from baseline warrants nutritional protein audit (target 1.6 to 2.2 g/kg lean body mass/day) and consideration of a structured progressive resistance program before continuing dose escalation.

Selective Estrogen Receptor Modulators (SERMs)

In premenopausal women with low estrogen states, or in breast cancer survivorship where AIs are not indicated, tamoxifen preserves estrogenic signaling in muscle tissue and may attenuate grip strength decline compared to AI alternatives. Direct head-to-head grip strength data are limited; this remains an area of active study.

What Low Grip Strength Means Clinically

A grip score below the EWGSOP2 cut-offs (<27 kg men, <16 kg women) signals more than weak hands.

Sarcopenia and Frailty

Low grip strength is one of three components of the EWGSOP2 sarcopenia definition (alongside low muscle mass and poor physical performance). The 2019 EWGSOP2 consensus paper recommends grip strength as the first-line muscle function test in clinical practice, ahead of gait speed and chair stand tests, because of its predictive validity and low equipment cost [3].

Cardiovascular and Metabolic Risk

The Prospective Urban Rural Epidemiology (PURE) study data confirmed that grip strength is inversely associated with incident cardiovascular disease. Patients in the lowest grip-strength quartile had a hazard ratio of 1.38 (95% CI 1.24 to 1.53) for major cardiovascular events compared to the highest quartile, independent of conventional cardiovascular risk factors [1].

Insulin Resistance

Skeletal muscle is responsible for approximately 75 to 80% of postprandial glucose disposal. Low muscle mass and function associate with insulin resistance independently of fat mass. A cross-sectional study in Diabetes Care (N=6,913) found that grip strength was inversely associated with HbA1c and fasting glucose, with the association strongest in adults over 50 [15].

What High Grip Strength Means

High grip strength, generally defined as readings above the 90th percentile for age and sex, is not a clinical concern in most contexts. It reflects well-preserved neuromuscular function and typically associates with lower mortality, better metabolic health, and longer healthspan.

When High Scores Warrant Attention

In rare cases, unexpectedly high grip strength in the context of systemic illness could reflect acromegaly (excess GH/IGF-1), early-stage myotonia, or other neuromuscular conditions. These diagnoses are supported by clinical history, IGF-1 levels, and electromyography, not grip strength alone. An isolated high reading in a healthy, active patient requires no additional workup.

How to Raise Grip Strength: Evidence-Based Strategies

Resistance Training

Progressive resistance training (PRT) produces the most consistent grip strength improvements across all age groups. A Cochrane review of 121 RCTs (N=6,700+) confirmed that PRT significantly increases muscle strength in older adults, with effect sizes consistent across men and women [16]. Twice-weekly sessions targeting compound upper-body and lower-body movements, progressed over 12 to 16 weeks, typically produce grip improvements of 4 to 8 kg in previously sedentary adults.

Protein Intake Optimization

Dietary protein at 1.6 g/kg/day is the minimum threshold for muscle protein synthesis optimization in adults under anabolic resistance conditions. The PROT-AGE study group recommendations advise 1.0 to 1.2 g/kg/day for healthy older adults and 1.2 to 1.5 g/kg/day for those with acute or chronic illness [17]. Leucine-rich sources (whey protein, animal protein) are more effective per gram than plant-derived equivalents for muscle protein synthesis rate.

Addressing Drug-Related Suppression

Where a drug is causing measurable grip strength decline, the most effective intervention is dose reduction or substitution when clinically appropriate. For patients who cannot discontinue the offending agent (e.g., patients on long-term ADT or corticosteroids), resistance training and optimized protein intake are the primary mitigation strategies, with grip strength re-tested every 12 weeks to track trajectory.

How to Lower Grip Strength (and Why the Question Matters)

Patients asking how to lower grip strength are usually asking one of two things: whether a physical demand or occupational test can be avoided, or whether a medical condition is expected to reduce their score over time. Voluntary suppression of grip strength during a clinical test is possible but detectable. Most dynamometer-based protocols include validity metrics (coefficient of variation across trials). A CV above 15% suggests submaximal effort and flags the result for clinical review.

Pathological causes of grip strength decline include: worsening sarcopenia, progressive neurological disease (ALS, Parkinson disease, multiple sclerosis), and untreated hypogonadism. Addressing the underlying condition is the only evidence-based approach to reversing the trajectory.